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The 8th Annual Summer Seminar: Gina Kolata
Science Writer, The New York Times
__________________________________________
The Office of Health Policy and Clinical Outcomes hosted the 8th Annual Summer
Seminar on July 12, 2002. Gina Kolata, keynote speaker and award-winning science
reporter for The New York Times, addressed over 150 healthcare professionals in her
presentation entitled “Beyond Cloning.”
Kolata, a science writer for nearly 30 years, began by recalling her first encounter in
1997 with the concept of cloning. “It sounded like an incredible long shot,” she
remembered thinking before reading the article published in Nature in which British
researchers reported creating a lamb using DNA from adult sheep. Kolata
subsequently followed up with a front-page story for the Times. “It was how the
world came to know that cloning actually succeeded,” she said.
Since she first broke the story of cloning, Kolata, who holds a master's degree in
mathematics from the University of Maryland, has emerged as a key news writer on
the topic. She is also the author of “Clone: The Road to Dolly, and the Path Ahead”
(William Morrow, 1999), a journalist’s account of the creation of the first cloned
sheep and its scientific and ethical implications.
The issue of cloning ties into stem cell research, another area that Kolata said is full
of high expectations. She explained in simple terms the complex difficulties of stem
cell research, such as identifying stem cells in tissue cultures that contain numerous
types of cells. “There is an obsessive optimism about how stem cell research is going
to treat disease,” she said, comparing the over-promise of stem cell therapy to that
of gene therapy.
Journalists play a difficult role in communicating the achievements of science
accurately, and Kolata emphasized the care that must be taken when interacting
with scientists who are eager to get their views published. “As a journalist, I always
ask a lot of questions and ask to see data and have them explained.”
From a journalist’s perspective, Kolata is cautiously optimistic about the future of
therapeutic cloning and controlling diseases through stem cell therapy. While it is not
right around the corner, “it’s at least envisionable,” she said, but added, “Hype and
hope continually get ahead of reality. What you hear and what’s happening are not
always the same thing.”
Kolata’s presentation was followed by comments from a reactor panel that included
Elizabeth A. Mansfield, PhD, Biologist and Senior Reviewer for the Immunology and
Molecular Diagnostics Division of Clinical Lab Devices in the Office of Drug Evaluation
in the Food and Drug Administration, and Thomas Jefferson faculty members Kay
Huebner, PhD, Professor, Kimmel Cancer Center; Bruce M. Boman, MD, PhD,
Director of the Division of Genetic and Preventive Medicine; and Timothy Block, MD,
Professor of Biochemistry and Molecular Pharmacology.
For information about upcoming events at the Office of Health Policy, please call
(215) 955-6969 or visit www.tju.edu/OHP/.
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